Download MendeleyDesign, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRAS G12C.
Li, A., Li, S., Wang, P., Dang, C., Fan, X., Chen, M., Liu, D., Li, F., Liu, H., Zhang, W., Wang, Y., Wang, Y.(2025) J Med Chem 68: 2422-2436
- PubMed: 39875337
- DOI: https://doi.org/10.1021/acs.jmedchem.4c02939
- Primary Citation of Related Structures:
9KPM, 9KPN - PubMed Abstract:
KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS G12C mutation is commonly found in non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). Inhibitors that covalently modify the mutated codon 12 cysteine have completed proof-of-concept studies in the clinic. Here, we describe structure-based design and cocrystal-aided drug optimization of a series of compounds with the 1,8-naphthyridine-3-carbonitrile scaffold. Biopharmaceutical optimization of the resulting leads to improve the solubility of the compounds and block the possible metabolic hotspots led to the identification of JAB-21822, a covalent KRAS G12C inhibitor with high potency and excellent cross-species pharmacokinetic properties. JAB-21822 has finished the pivotal Phase II clinical trials in NSCLC, and a new drug application was submitted to the National Medical Products Administration in 2024.
- Medicinal Chemistry Department, Jacobio Pharmaceuticals Group Co., Ltd., Beijing 100176, P. R. China.
Organizational Affiliation:
